Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance
NCT ID: NCT06010745
Last Updated: 2023-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
101 participants
INTERVENTIONAL
2023-08-11
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Assess the Safety and Effectiveness of Plant-based Biotin and Plant Based Biotin with Silica in Healthy Human Subjects with Complaints of Hair Fall, Thin, Dry, & Brittle Hair, and Dry Skin
NCT05972512
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
NCT06362941
Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals with Self-Perceived Thinning Hair
NCT06605768
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
NCT06146166
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
NCT03709563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hair thinning and hair loss are problems that affect both men and women. A variety of diet, lifestyle, life-stage, ethnicity/race, and genetic factors contribute to the thinning and loss of hair. While hair loss is not a condition that is life-threatening, it is life-impacting. Hair loss negatively affects confidence and is associated with decline in quality of life While FDA-approved treatments do exist, access or ease of use may be difficult, or use limited to men. Ingredients like biotin, silicon, and herbals have been marketed for hair, skin, and nail benefits. The studies on their benefits are equivocal, requiring continued research investments to guide evidence-based recommendations for use. The availability of an oral supplement that is safe and effective for everyday use may present a new option for men and women concerned with hair thinning or hair loss.
Specific aims The objective of this randomized, triple-blind, placebo-controlled study is to assess the effectiveness of a novel dietary ingredient formulated with 10 mg of biotin and 10 mg of silicon for improving the appearance of hair and skin in a generally healthy adult population. The primary aim of this study will be to evaluate the impact of daily use on hair growth. In addition, the impact of supplementation on other hair and skin parameters will be evaluated. The study will include both analytical measures and a subjective questionnaire in order to connect analytical outcomes with observable changes in appearance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Open-label products will be made with the active ingredients and this product will be labeled as an active - with no masking of identity to study sponsor, clinical site, or study participants.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active capsules
Dietary ingredient standardized to deliver 10 mg of biotin and 10 mg of silicon per serving (1 capsule/serving).
Biotin and silicon
The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
Placebo capsules
The placebo comparator contains only inert ingredients (1 capsule/serving)
Placebo
Inert ingredients only
open label
Open-label arm that will involve men who only receive the active dietary ingredient capsules. This arm will run in parallel with the blinded study conducted in women.
Biotin and silicon
The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biotin and silicon
The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
Placebo
Inert ingredients only
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good general health as determined by ALS staff.
* Individuals who, at baseline, are free of any dermatological or systemic disorder, which would interfere with the results, at the discretion of the Investigator.
* Individuals who agree to provide a comprehensive medical history and concomitant medication list for review by ALS staff.
* Individuals who will read, understand and sign an informed consent document and photography release form.
* Individuals who agree to use the test product as instructed by the testing facility and complete the full course of the study.
* Individuals who agree to maintain a stable lifestyle with no significant changes in diet, supplements, medications, or exercise routine.
* Individuals who agree to maintain a consistent routine of washing their hair and skin.
* Individuals with natural hair only at start and for the duration of trial (no extensions, weaves, pieces, etc.). Dyed hair will be permitted for individuals who agree to maintain the same hair color for the study duration.
* Individuals who have not participated in another clinical study or for the past 30 days and agree to not concurrently participate in any other studies.
* Individuals who will agree to continue to use their current personal care products (e.g. shampoo, conditioner, hair spray, mousse, lotions, creams, sunscreen, cosmetics, etc.) for the duration of the study and agree to not incorporate any new products with the exception of those provided by ALS. Subjects must have a safe use history of their current products for at least 30 days prior to screening.
* Individuals who agree to maintain the same length, hair styling and coloring practices for the duration of the study.
* Individuals who agree not to utilize any new over the counter, commercial or other products that are marketed and promoted for enhancing aspects of their hair or skin (e.g., Viviscal®, BioSil®, Nutrafol®, etc.) for the entire duration of the study and confirms not using them one month prior to screening. This includes biotin-based supplements that provide 1000 micrograms or more biotin and/or contain biotin in combination with other ingredients promoted for hair and skin benefits.
* Individuals who agree to refrain from strenuous activity/exercise for at least 24 hours prior to each study visit.
* Individuals who agree to refrain from alcohol-containing food or beverages for at least 24 hours prior to each study visit.
* Individuals who agree to visit a 3rd party off-site laboratory and participate in a blood draw (N=40).
* Individuals who agree to avoid all tanning (sun or artificial such as tanning beds, sprays and other topical applications) and excessive sun exposure for the entire duration of the study and confirms avoiding these elements for 2 weeks prior to screening.
Exclusion Criteria
* Individuals with an active (flaring) disease or chronic skin allergies (atopic dermatitis, eczema, psoriasis, severe acne), or had recently treated skin cancer (within the last 12 months) or currently undergoing treatment for cancer.
* Individuals with a history of drug or alcohol abuse in the 12 months prior to screening.
* Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara) and/or radiation as determined by study documentation.
* Individuals with damaged skin at or in close proximity to test sites (e.g., sunburn, tattoos, scars, excessive hair, or other disfigurations) that would impact study assessments.
* Individuals having severe hair loss or are completely bald.
* Individuals with white or very light-colored hair that is not able to be analyzed using the outlined instrumentation.
* Individuals who have any history, which, in the Investigator's opinion, indicates the potential for harm to the subject or could place the validity of the study in jeopardy.
* Individuals who have had any medical procedure, such as laser resurfacing, microdermabrasion, retinol or AHA treatments, hyaluronic injections, collagen, or chemical peels to the test sites within the last 6 months (including Botox, Restylyn, or other fillers).
* Individuals who are currently using or during the last 6 months have used, Retin A, or other Rx/OTC Retinyl A, or other astringent derived products or alpha hydroxyl acid treatments for photo-aging and fine lines/wrinkles.
* Individuals who have used any products or devices to promote scalp hair growth (e.g., finasteride, minoxidil, Rogaine, Propecia) within 6 months of screening; or refusal to refrain from any of these for the study duration.
* Individuals who have started, stopped, or changed hormone replacement therapy (HRT) within 6 months prior to screening.
* Subjects with history or presence of any clinically significant cardiovascular (light headedness/fainting or drops in blood pressure or recent myocardial infarction), respiratory (including uncontrolled asthma or allergies), renal, hepatic, gastrointestinal, hematologic, neurologic, any type of cancer that required radiation and/or chemotherapy for 1 year prior to study, metabolic disease or disorder, including guanidinoacetate methyltransferase deficiency and herpes (HSV-1), or any uncontrolled medical illness which in the opinion of the Investigator would jeopardize the safety of the subject, interfere with study assessments, or impact the validity of the study.
* Individuals who indicate that they are pregnant, planning a pregnancy or nursing.
* Individuals who have been medically diagnosed with Type I Diabetes.
* Individuals who have a known history of hypersensitivity to any cosmetics, personal care products, and/or fragrances.
* Individuals who are employees of the company.
35 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALS Beauty and Personal Care
INDUSTRY
Nutrition 21, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordan DeSantis
Role: PRINCIPAL_INVESTIGATOR
ALS Beauty and Personal Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ALS Beauty and Personal Care
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kalman, D. S., & Hewlings, S. J. (2021). A Randomized Double-Blind Evaluation of a Novel Biotin and Silicon Ingredient Complex on the Hair and Skin of Healthy Women. Journal of Clinical & Experimental Dermatology Research, 12(1), 1-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALS 23-029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.